Answer
Blinatumomab should be used during pregnancy only if the potential benefit outweighs the potential risk to the foetus; following exposure, newborns should be monitored for B-cell depletion and live-virus vaccinations postponed until their B-cell count recovers.
Sources for this answer
- BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusionAmgen Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 26Document updated
Sources checked